A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

Summary

The primary purpose of this study is to investigate the fate of ACT-132577 in healthy subjects and in people with severe kidney disease

Timeline

Start

2017-06-03

Primary completion

2017-10-27

Completion

2017-10-27

Publications

• Background Sidharta PN, Ulc I, Dingemanse J. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment. Clin Drug Investig. 2019 Nov;39(11):1117-1123. doi: 10.1007/s40261-019-00837-x.

Drugs

Indications

No indication recorded.